The FDA has approved Novartis Coartem Baby, the first malaria treatment designed for newborns and young infants.
The medicine, developed in collaboration with Medicines for Malaria Venture, a nonprofit partnership, is intended for babies weighing less than 10 pounds, an age group previously left without an approved option, according to a July 8 news release from Novartis.
The new formulation, also known as Riamet Baby in other countries, was developed to help close the treatment gap that has forced healthcare providers to use older children’s medications off label, raising the risk of incorrect dosing, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
